LITTLE KNOWN FACTS ABOUT BMS-199264 HYDROCHLORIDE.

All enrolled patients who acquired at least just one dose of zosuquidar or placebo for the duration of induction were being monitored for the occurrence of adverse situations (439 individuals, 219 on zosuquidar and 210 on placebo). The most typical adverse gatherings were being linked to the duration of extended and sizeable myelosuppression as is